잠시만 기다려 주세요. 로딩중입니다.

Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy

Endocrinology and Metabolism 2020년 35권 3호 p.602 ~ 609
Jin Meihua, 안종화, 이유미, 성태연, 김원구, 김태영, 류진숙, 김원배, 송영기, 전민지,
소속 상세정보
 ( Jin Meihua ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
안종화 ( Ahn Jong-Hwa ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
이유미 ( Lee Yu-Mi ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
성태연 ( Sung Tae-Yon ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
김원구 ( Kim Won-Gu ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
김태영 ( Kim Tae-Yong ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
류진숙 ( Ryu Jin-Sook ) - University of Ulsan College of Medicine Asan Medical Center Department of Nuclear Medicine
김원배 ( Kim Won-Bae ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
송영기 ( Shong Young-Kee ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine
전민지 ( Jeon Min-Ji ) - University of Ulsan College of Medicine Asan Medical Center Department of Internal Medicine

Abstract


Background: The optimal dose of radioactive iodine (RAI) therapy for N1b papillary thyroid carcinoma (PTC) is controversial. We evaluated the clinical outcome of N1b PTC patients treated with either 100 or 150 mCi of RAI.

Methods: We retrospectively analyzed N1b PTC patients who underwent total thyroidectomy and postoperative RAI therapy at a tertiary referral center between 2012 and 2017. As the baseline characteristics differed between treatment groups, we performed exact matching for various pathological factors according to RAI dose. We evaluated the response to therapy and recurrence-free survival (RFS) in the matched patients. Structural recurrent/persistent disease was defined as new structural disease detected after initial therapy, which was confirmed by cytology or pathology.

Results: Of the total 436 patients, 37 (8.5%) received 100 mCi of RAI and 399 (91.5%) received 150 mCi of RAI. After an exact 1:3 matching, 34 patients in the 100 mCi group and 100 patients in the 150 mCi group remained. There was no significant difference in response to therapy between the groups in the matched population (P=0.63). An excellent response was achieved in 70.6% (n=24) of patients in the 100 mCi group and 76.0% (n=76) in the 150 mCi group. Two (5.9%) patients in the 100 mCi group and four (4.0%) in the 150 mCi group had recurrence and there was no significant difference in RFS between the groups in the matched population (P=0.351).

Conclusion: There were no differences in response to therapy and RFS in N1b PTC patients according to RAI dose.

키워드

Thyroid neoplasms; Neoplasm metastasis; Recurrence

원문 및 링크아웃 정보

등재저널 정보

SCI(E)
MEDLINE
KCI
KoreaMed
KAMS